BioApatIgG- Low cost and high performance serological diagnosis

In December 2019, the World Health Organization was informed of a set of pneumonia cases of unknown etiology in Wuhan, China. Several subsequent investigations have identified a new coronavirus, now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in samples from affected patients. The highly sensitive and specific laboratory diagnosis is important for the rapid control of the evolution of Coronavirus disease associated with SARS-CoV-2 2019 (COVID-19). In Brazil, on February 26, the first patient with COVID-19 was diagnosed and registered. Since then, the curve of new cases has grown logarithmically and the demand for inputs for fast and accurate tests is a very important need. Currently, molecular tests for the detection of viral RNA in human fluids are recommended by the Center for Disease Control and Prevention (CDC). However, detection tests for monitoring people who have already developed immunity to the disease are of fundamental importance for real monitoring of viral progress. In Brazil, inputs for the production of both molecular tests and immunoassays are imported, and with the advance of the pandemic, the logistics of materials and high prices lead to the need for local production of biotechnological inputs for use in immunoassays and molecular tests. Given this, BIOLINKER, a company specialized in rapid protein synthesis with an in vitro transcription and translation system, proposes in partnership with Professor Ester Sabino of the Institute of Tropical Medicine and the Virology group at UFRJ of Professor Almidar Tanuri, to provide standardized ELISA reaction kits for the detection of circulating IgG against the COVID-19 virus in patient sera . Our results with the aptamer, validated during the PIPE phase 1, showed high affinity and specificity for the human IgG constant fraction. We foresee the use of this aptamer developed in PIPE-phase 1 of the 201722801-6 process conjugated with biotin and the detection through peroxidase conjugated with avidin which is another input easily produced by BIOLINKER. We will evaluate the detection of patient serum IgG against the nucleocapsid N antigens, the antigenic fraction of the spike protein RBS (spike receptor binding region). Our objective with this promotion is to establish a scale of production of the antigens that we are already screening in search of antigenic regions and that we initially produced in a "cell-free" or cell-free system, and then immobilize them in ELISA plates to the degree with a purity of 85%, in addition to manufacturing anti-IgG buffers and aptamer conjugated with biotin to detect IgG in the serum of patients in screening, together with the Institute of Tropical Medicine - FM-USP. Thus, we enable a fast and very low cost trial for epidemiological screening of the disease. Our estimated costs are low, since the production of aptamers is relatively low cost, as well as the production of antigen via "cell-free", since the company has its own expression plasmids and protocols already established. (AU) and then immobilize them in ELISA plates at a purity level of 85%, in addition to manufacturing buffers and anti-IgG aptamer conjugated to biotin for detection of IgG in the serum of patients being screened, together with the Institute of Tropical Medicine - FM-USP. Thus, we enable a fast and very low cost trial for epidemiological screening of the disease. Our estimated costs are low, since the production of aptamers is relatively low cost, as well as the production of antigen via "cell-free", since the company has its own expression plasmids and protocols already established. (AU) and then immobilize them in ELISA plates at a purity level of 85%, in addition to manufacturing buffers and anti-IgG aptamer conjugated to biotin for detection of IgG in the serum of patients being screened, together with the Institute of Tropical Medicine - FM-USP. Thus, we enable a fast and very low cost trial for epidemiological screening of the disease. Our estimated costs are low, since the production of aptamers is relatively low cost, as well as the production of antigen via "cell-free", since the company has its own expression plasmids and protocols already established. (AU) together with the Institute of Tropical Medicine - FM-USP. Thus, we enable a fast and very low cost trial for epidemiological screening of the disease. Our estimated costs are low, since the production of aptamers is relatively low cost, as well as the production of antigen via "cell-free", since the company has its own expression plasmids and protocols already established. (AU) together with the Institute of Tropical Medicine - FM-USP. Thus, we enable a fast and very low cost trial for epidemiological screening of the disease. Our estimated costs are low, since the production of aptamers is relatively low cost, as well as the production of antigen via "cell-free", since the company has its own expression plasmids and protocols already established.